Login to Your Account

Poniard's Pipeline Narrows to Picoplatin After Cost Cutting

By Catherine Hollingsworth

Monday, March 23, 2009
Poniard Pharmaceuticals Inc. is cutting 12 percent of its staff and discontinuing in-house preclinical research operations, the latest in a recent spate of layoffs. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription